Anticancer carbonic anhydrase inhibitors: a patent and literature update 2018-2022

SG Nerella, P Singh, M Arifuddin… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Cancer affects an increasing number of patients each year with an
unacceptable death toll worldwide. A new therapeutic approach to combat tumors consists …

A decade of tail-approach based design of selective as well as potent tumor associated carbonic anhydrase inhibitors

A Kumar, K Siwach, CT Supuran, PK Sharma - Bioorganic Chemistry, 2022 - Elsevier
Human carbonic anhydrase (hCA) isoforms hCA IX and hCA XII are well established
anticancer drug targets and their selective inhibition is highly desired for the proper …

Carbonic anhydrase IX inhibitors in cancer therapy: an update

CT Supuran, JY Winum - Future medicinal chemistry, 2015 - Taylor & Francis
Carbonic anhydrases (CAs; EC 4.2. 1.1) are well known zinc metalloproteins involved in the
catalysis of a very simple but essential physiological reaction: carbon dioxide hydration to …

Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008–2018)

A Nocentini, CT Supuran - Expert Opinion on Therapeutic Patents, 2018 - Taylor & Francis
Introduction: Human carbonic anhydrases (CA, EC 4.2. 1.1) IX and XII are tumor-associated
proteins, being part of the molecular machinery that tumor cells build as adaptive responses …

Anticancer carbonic anhydrase inhibitors: a patent review (2008–2013)

SM Monti, CT Supuran, G De Simone - Expert opinion on …, 2013 - Taylor & Francis
Introduction: Human carbonic anhydrases (EC 4.2. 1.1) IX (hCA IX) and XII (hCA XII) are two
tumor-associated proteins, being overexpressed in many tumors and involved in critical …

[HTML][HTML] Tumor associated carbonic anhydrase inhibitors: rational approaches, design strategies, structure activity relationship and mechanistic insights

SG Nerella, PS Thacker, M Arifuddin… - European Journal of …, 2024 - Elsevier
The emergence of tumor-associated human carbonic anhydrases (hCA) as promising
therapeutic targets has urged rigorous research into the development of potent and selective …

Cancer drug development of carbonic anhydrase inhibitors beyond the active site

S Singh, CL Lomelino, MY Mboge, SC Frost… - Molecules, 2018 - mdpi.com
Carbonic anhydrases (CAs) catalyze the reversible hydration of carbon dioxide to produce
bicarbonate and a proton. Multiple CA isoforms are implicated in a range of diseases …

Glycosidic carbonic anhydrase IX inhibitors: a sweet approach against cancer

JY Winum, PA Colinas, CT Supuran - Bioorganic & medicinal chemistry, 2013 - Elsevier
Targeting tumour associated carbonic anhydrase (CA, EC 4.2. 1.1) isoforms IX and XII is
now considered as a pertinent approach for the development of new cancer therapeutics …

How many carbonic anhydrase inhibition mechanisms exist?

CT Supuran - Journal of enzyme inhibition and medicinal chemistry, 2016 - Taylor & Francis
Six genetic families of the enzyme carbonic anhydrase (CA, EC 4.2. 1.1) were described to
date. Inhibition of CAs has pharmacologic applications in the field of antiglaucoma …

Mapping selective inhibition of the cancer-related carbonic anhydrase IX using structure–activity relationships of glucosyl-based sulfamates

BP Mahon, CL Lomelino, J Ladwig… - Journal of Medicinal …, 2015 - ACS Publications
Inhibition of human carbonic anhydrase IX (hCA IX) has shown to be therapeutically
advantageous for treating many types of highly aggressive cancers. However, designing …